Literature DB >> 19816811

Cerebral vasospasm and concurrent left ventricular outflow tract obstruction: requirement for modification of hyperdynamic therapy regimen.

Gabriel Zada1, Sergei Terterov, Jonathan Russin, Leonardo Clavijo, Steven Giannotta.   

Abstract

BACKGROUND: Medical treatment of arterial vasospasm following aneurysmal subarachnoid hemorrhage (SAH) generally consists of triple H therapy, which frequently relies on inotropic agents in order to increase cardiac output (CO). Patients with concurrent left ventricular outflow tract (LVOT) obstruction may have paradoxical decreases in CO following administration of inotropic pressors, placing them at significant risk for cerebral ischemia and stroke.
METHODS: The clinical courses of two patients with SAH-induced arterial vasospasm and underlying left ventricular outflow obstruction are reported. Both patients had hypotension and low cardiac output that were refractory to medical management with triple H therapy. Echocardiography in both patients demonstrated LVOT obstruction secondary to hypertrophic obstructive cardiomyopathy (HOCM).
RESULTS: Intervention in both patients included discontinuation of inotropic agents and maintenance of hypervolemia to a target pulmonary capillary wedge pressure range, resulting in improved cardiac output and mean arterial pressure.
CONCLUSION: Medical treatment for cerebral vasospasm with inotropic pressor agents may result in paradoxical decreases in hemodynamic parameters and cerebral perfusion in patients with LVOT obstruction. While HOCM is the most likely structural abnormality to cause this phenomenon, it can be induced by several physiological conditions encountered in the neurocritical care setting. Modifications in triple H therapy regimens may be required in order to optimize cerebral perfusion and prevent cerebral ischemia and stroke in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19816811     DOI: 10.1007/s12028-009-9286-9

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  23 in total

1.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

2.  Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy.

Authors:  K Okeie; M Shimizu; H Yoshio; H Ino; M Yamaguchi; T Matsuyama; T Yasuda; J Taki; H Mabuchi
Journal:  J Am Coll Cardiol       Date:  2000-09       Impact factor: 24.094

3.  Hyperdynamic therapy for cerebral vasospasm.

Authors:  H Hadeishi; M Mizuno; A Suzuki; N Yasui
Journal:  Neurol Med Chir (Tokyo)       Date:  1990-05       Impact factor: 1.742

4.  Left ventricular outflow tract obstruction as a cause for hypotension and symptoms during dobutamine stress echocardiography.

Authors:  M J Sorrentino; R H Marcus; R M Lang
Journal:  Clin Cardiol       Date:  1996-03       Impact factor: 2.882

5.  Provokable left ventricular outflow tract obstruction in a patient without hypertrophy.

Authors:  Ferdinando Pasquale; Maria Teresa Tomé-Esteban; Riccardo Morgagni; Perry Elliott
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

6.  Acute subarachnoid haemorrhage as a precipitant for takotsubo cardiomyopathy: a case report and discussion.

Authors:  Moloy Das; Simon Gonsalves; Arin Saha; Stuart Ross; Gordon Williams
Journal:  Int J Cardiol       Date:  2008-02-20       Impact factor: 4.164

Review 7.  Peri-operative measures for treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.

Authors:  Ali Alaraj; Fady T Charbel; Sepideh Amin-Hanjani
Journal:  Neurol Res       Date:  2009-01-07       Impact factor: 2.448

Review 8.  Peri-operative medical management of cerebral vasospasm.

Authors:  Eric Michael Deshaies; Alan S Boulos; A John Popp
Journal:  Neurol Res       Date:  2009-01-07       Impact factor: 2.448

9.  Dobutamine induced dynamic left ventricular outflow tract obstruction in patients with hypertrophic nonobstructive cardiomyopathy.

Authors:  Osman Bolca; Nihat Ozer; Mehmet Eren; Bahadir Dağdeviren; Tugrul Norgaz; Osman Akdemir; Tuna Tezel
Journal:  Tohoku J Exp Med       Date:  2002-10       Impact factor: 1.848

10.  Cardiac performance enhancement from dobutamine in patients refractory to hypervolemic therapy for cerebral vasospasm.

Authors:  M L Levy; C H Rabb; V Zelman; S L Giannotta
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

View more
  4 in total

1.  Seeking new approaches: milrinone in the treatment of cerebral vasospasm.

Authors:  Antoine Baumann; Anne-Laure Derelle; Paul-Michel Mertes; Gérard Audibert
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 2.  Hemodynamic management of subarachnoid hemorrhage.

Authors:  Miriam M Treggiari
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

3.  Continuous cardiac output and near-infrared spectroscopy monitoring to assist in management of symptomatic cerebral vasospasm after subarachnoid hemorrhage.

Authors:  Tatsushi Mutoh; Tatsuya Ishikawa; Akifumi Suzuki; Nobuyuki Yasui
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

4.  Impact of transpulmonary thermodilution-based cardiac contractility and extravascular lung water measurements on clinical outcome of patients with Takotsubo cardiomyopathy after subarachnoid hemorrhage: a retrospective observational study.

Authors:  Tatsushi Mutoh; Ken Kazumata; Shunsuke Terasaka; Yasuyuki Taki; Akifumi Suzuki; Tatsuya Ishikawa
Journal:  Crit Care       Date:  2014-08-12       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.